Breviscapine alleviates NASH by inhibiting TGF‐β‐activated kinase 1‐dependent signaling

BACKGROUND AND AIMS: NAFLD is a key component of metabolic syndrome, ranging from nonalcoholic fatty liver to NASH, and is now becoming the leading cause of cirrhosis and HCC worldwide. However, due to the complex and unclear pathophysiological mechanism, there are no specific approved agents for tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lan, Tian, Jiang, Shuo, Zhang, Jing, Weng, Qiqing, Yu, Yang, Li, Haonan, Tian, Song, Ding, Xin, Hu, Sha, Yang, Yiqi, Wang, Weixuan, Wang, Lexun, Luo, Duosheng, Xiao, Xue, Piao, Shenghua, Zhu, Qing, Rong, Xianglu, Guo, Jiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299589/
https://www.ncbi.nlm.nih.gov/pubmed/34717002
http://dx.doi.org/10.1002/hep.32221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299589/
https://www.ncbi.nlm.nih.gov/pubmed/34717002
http://dx.doi.org/10.1002/hep.32221

Ejemplares similares